



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

April 24, 2008

Docket No. 03002539
Control No. 142292

License No. 29-11935-01

Michael R. D'Agnes
President and CEO
Raritan Bay Medical Center
530 New Brunswick Avenue
Perth Amboy, NJ 08861

SUBJECT: RARITAN BAY MEDICAL CENTER, LICENSE AMENDMENT, CONTROL NO.
142292

Dear Mr. D'Agnes:

This refers to your license amendment request. Enclosed with this letter is the amended license removing Dr. Federman. In addition, please note that Item 9.C. and corresponding physician authorizations were revised to remove use of iodine-131 greater than 33 millicuries, since your license does not currently list any physician with this experience.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Regulations, Guidance, and Communications**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 56

M. D'Agnes
Raritan Bay Medical Center

2

cc:
Marvin Platt, M.D., Radiation Safety Officer

DOCUMENT NAME: C:\FileNet\ML081210574.wpd

SUNSI Review Complete: PLanzisera

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	<input checked="" type="checkbox"/> N	DNMS/RI	<input type="checkbox"/>	DNMS/RI	<input type="checkbox"/>	<input type="checkbox"/>
NAME	PLanzisera/PL						
DATE	4-24-08						

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Raritan Bay Medical Center</p> <p>2. 530 New Brunswick Avenue Perth Amboy, New Jersey 08861</p>	<p>In accordance with the letter dated April 2, 2008,</p> <p>3. License number 29-11935-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date June 30, 2012</p> <hr/> <p>5. Docket No. 030-02539;29-20580-01 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1 curie</p>
--	---	---

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, except sodium iodide iodine-131 in quantities greater than 33 millicuries, for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 530 New Brunswick Avenue, Perth Amboy Division, Perth Amboy, New Jersey and One Hospital Plaza, Old Bridge Division, Old Bridge, New Jersey.
11. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-11935-01

Docket or Reference Number
030-02539;29-20580-01

Amendment No. 56

B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Marvin Platt, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Arnold Derman, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Stuart Kotler M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Robert Einhorn, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Steven Warren, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Ronald Kolber, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Lawrence S. Chaise, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Anthony Chiaramida, M.D.	35.100; 35.200
Norman Sorkin, M.D.	35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131
Evangeline A. Luna, M.D.	35.100; 35.200
Mark Moshiyakhov, M.D.	35.100; 35.200
Myron Levitt, M.D.	35.100; 35.200
Laura Anne Grygotis, M.D.	35.100; 35.200
Phili Lakritz, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-11935-01

Docket or Reference Number
030-02539;29-20580-01

Amendment No. 56

Authorized Users

Scott Schlesinger, M.D.

Material and Use

35.100; 35.200; 35.300, except oral administration of greater than 33 millicuries of sodium iodide I-131

12. The Radiation Safety Officer for this license is Marvin Platt, M.D.
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated February 8, 2002 (ML020430053)
B. Letter dated May 30, 2002 (ML021580139)
C. Letter dated February 8, 2005 (ML050730437)

For the U.S. Nuclear Regulatory Commission

Date April 24, 2008

By **Original signed by Penny Lanzisera**
Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406